July 21, 2022 7:52am

Verve Therapeutics (VERV) prices $225 M offering at $27.00 as stock slips -$6.63 or -18.46% in pre-market

Pre-open indications: 6 Negative Indication and 1 Puff/Pump/Promote

RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.

The 8:00 A.M., ET edition

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.


Dow futures are DOWN -0.33% or (-105 points), S&P futures are DOWN -0.26% (-10 points) and NASDAQ futures are DOWN -0.06% (-7 points) early in the pre-open – so far,


Stock futures are fluctuating on Thursday pre-supposing a negative open,

European stocks were slightly lower,

Asia pacific stocks were mixed as MSCI’s broadest index <of Asia-Pacific shares outside Japan> was fractionally lower.



U.S. stocks ended higher on Wednesday with the Nasdaq booking a 1.6 % gain on positive earnings signals with a wary eye on inflation and more interest rate hikes by the Fed.

Wednesday, indexes backed off session highs. The Nasdaq and the cell and gene therapy sector held onto much of their sizable moves. The S&P 500 pared modest gains to around its June peaks; while the Dow still held above its 50-day line.


RegMed Investors’ (RMi) closing bell: upside strength sustains. Impressed as algo “raiders” haven’t ambushed share pricings, they’re coming because there's a lot of pessimism just below sentiment’s surface.”https://www.regmedinvestors.com/articles/12525


Ebb and flow –

Q3/22 – 1 holiday, 4 negative and 9 positive closes

Q2/22 –

June – 1 holiday, 9 positive and 11 negative closes

·         May - 11 positive and 10 negative closes

·         April - 1 holiday, 6 positive and 13 negative closes


·         March – 13 negative and 10 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes


Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS

Negative indications:

Sage Therapeutics (SAGE) closed up +$3.62 to $35.91 after Tuesday’s +$1.72 and Monday’s -$1.07 with a negative -$0.03 or -0.08% pre-open indication,

CRISPR Therapeutics (CRSP) closed down -$1.44 to $82.34 after Tuesday’s +$4.42 and Monday’s -$4.03 with a negative -$0.19 or -0.23% pre-open indication,

Regenxbio (RGNX) closed up +$1.16 to $32.79 after Tuesday’s +$1.26 and Monday’s -$1.22 with a negative -$1.63 or -4.97% pre-open indication,

Verve Therapeutics (VERV) closed up +$3.62 to $35.81 after Tuesday’s +$5.98, Monday’s +$2.60 and Friday’s -$0.49 and last Thursday’s -$0.97 with a negative -$6.63 or -18.46% pre-open indication,

uniQure NV (QURE) closed up +$0.39 to $24.47 with a negative -$0.46 to $1.88% pre-open indication,

Beam Therapeutics (BEAM) closed up +$3.30 to $67.91 after Tuesday’s +$6.60 and Monday’s +$0.39 with a negative -$0.41 or -0.60% pre-open indication.


Puff/Pump and Promote: Maintaining SELL

Biostage (OTCQB: BSTG) closed flat with 21 shares traded after Tuesday’s +$0.01 with 300 shares traded, Monday’s flat at $5.00 with 1,319 shares traded, Friday’s -$1.00 to $5.00 with 10.658 shares traded and last Thursday’s +$0.12 to $6.00 <52-week low of $1.21> <3 mo. Average = 1,819 shares>

·         BSTG seems to have the ONLY avenue to finance to utilize non-U.S. Chinese investors?

·         How much lipstick is a lot on this pig with an almost 4-year-old IND and NO clinical trial initiation?

·         WATCH and be ready for a BIG reverse of shares to enable offering from multiple private placements as it tries to facilitate an offering with Newbridge Securities


The BOTTOM LINE: I try to keep it simple … and short!

Maintaining my theme, BEWARE sector dramatic daily highs … what goes up will spiral down!

Sector equity pricing are trending in a roller coaster fashion, currently being at the mercy of trading, inflation, interest rates and earnings.

We are up, down, up and down – it gets tiring! Portfolios are wailing, not crying.

Thin volumes keep trading volatile in, with the CBOE Volatility index closing <at 23.79 points> its lowest in nearly three months.

We always need a … villain and they are multiplying – low volume as “Earnings’ season is coming, investors NEED to focus on LPS (loss-per-share), collaboration revenues and cash positions i.e., runways”.

Upcoming earnings announcements: earnings as Alnylam Pharmaceuticals (ALNY) Q2 announcement on Thursday 7/28, Sage Therapeutics (SAGE) on Tuesday, 8/2 and AxoGen (AXGN) on Wednesday, 8/3.

Investors are going to need to prepare for another reporting cycle to confirm whether or not a bottom is even close to happening.

There is VALUE out there however, it’s about playing or betting the timing of the sector.

We are left with choosing to hang on to “our” portfolio position while it is a given that the sector shifts from fierce, sudden sell-offs to gaining altitude or ascending not to its value but, better than it was.

Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.


Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

All investments are subject to risks. Investors should consider investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.